Core Insights - Charles River Laboratories' Research Models and Services (RMS) business is benefiting from the Charles River Accelerator and Development Labs (CRADL) initiative, although the global business environment remains challenging, impacting growth [1] Group 1: Acquisitions and Business Strategy - In November 2023, the company acquired an additional 41% stake in Noveprim, resulting in a 90% controlling interest, which supports its nonhuman primate (NHP) supply strategy [2] - The acquisition of Explora Biolabs in April 2022 complements the company's Insourcing Solutions business and enhances its CRADL footprint [2] - The company is expanding CRADL's footprint through both organic growth and acquisitions to meet client demand for flexible laboratory space [5] Group 2: Market Challenges - Foreign exchange fluctuations, particularly the strengthening of the euro and other developed market currencies, are negatively affecting the company's international revenue performance [3] - A significant portion of RMS and DSA revenues is generated in China, where trade policy conflicts could hinder business development [6] - The Manufacturing Solutions segment is experiencing softness due to a post-COVID slowdown in demand from biopharma manufacturers and CDMOs [6] Group 3: Demand and Growth - RMS services are in high demand for basic research and screening of non-clinical drug candidates, providing clients with greater flexibility and supporting increased scientific complexity [4] - The insourcing solutions business is witnessing strong growth, driven by the adoption of CRADL's flexible model [5] - The RMS segment is benefiting from higher NHP revenues and broad-based growth in small research models across all geographic regions [4] Group 4: Product and Service Expansion - The company is broadening its product and service offerings across drug discovery and early-stage development through focused acquisitions, including Retrogenix and Vigene Biosciences [10] - The Microbial Solutions business is facing challenges due to reduced testing volumes and investments, but the company believes destocking activities are largely complete [11]

Charles River's Plasma DNA and Viral Vector CDMO Following the agreement, Gates Institution will have access to Charles River's manufacturing platforms and viral vector CDMO center of excellence, leveraging a range of services, including process development evaluation of Gates Institute's LVV backbone, phase-appropriate research grade, high–quality (HQ) plasmid DNA production and GMP LVV manufacturing. Image Source: Zacks Investment Research Given the market potential, the collaboration between Charles Rive ...

More on the News Industry Prospect In June 2024, Charles River announced a collaboration with MatTek Corporation to develop a New Approach Methodology inhalation toxicology test to reduce reliance on traditional animal research methods. The program will be funded through $1.3 million grant. Charles River currently carries a Zacks Rank #3 (Hold). The Inogen stock has surged 32.4% year to date. In the past 60 days, the bottom-line estimate for 2024 has narrowed from a loss of $2.56 per share to a loss of $2.4 ...

Outlook's 08/30/2023 CRL opened up a world of pain for its shareholders This is my second Outlook Therapeutics (NASDAQ:OTLK) article after 04/2023's "Outlook Therapeutics: August PDUFA For Wet AMD Blockbuster". In that article, I pegged Outlook as a high risk high reward bet on a successful PDUFA. I took the bullish bet, rating Outlook a Buy. In doing so, I noted: There is no wiggle room here. What happens if the FDA extends its PDUFA date by three months as quite common? What happens if the FDA issues a CR ...

The VCG collaboration is a project guided by Charles River's Alternative Methods Advancement Project ("AMAP"), an initiative focused on reducing the use of animals in research. The development is likely to boost the company's Discovery and Safety Assessment ("DSA") segment. As the company enters the next frontier of drug development, AMAP will facilitate strategic and purposeful investing to pave the path where more patients receive needed treatments and medicines safely, swiftly and successfully. Upholding ...

SAN DIEGO, June 06, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP (www.johnsonfistel.com), a shareholder rights law firm, announces its continuing investigation of whether certain directors and officers of Charles River Laboratories International, Inc. (NYSE: CRL) breached their fiduciary duties to CRL and its shareholders. What can I do? If you are a current Charles River shareholder, you may have legal claims that may be brought on behalf of the company, against CRL's directors and officers. If you wish to ...

Charles River Laboratories International, Inc. (CRL) is well-poised for the coming quarters, on the back of its impressive strategic acquisitions. Stabilization of demand trends within the DSA (Discovery and Safety Assessment) arm is encouraging. The company's sound solvency also instils optimism. However, concerns remain over the adverse impacts of macroeconomic challenges as well as currency fluctuations. In the past year, this Zacks Rank #3 (Hold) company's shares have risen 9.4% compared with 6.1% growt ...

Charles River Laboratories' (CRL) Research Models and Services (RMS) arm continues to gain from the CRADL initiative. Yet, destocking efforts are denting growth in the Manufacturing Solutions business. The stock carries a Zacks Rank #3 (Hold) currently. Within Charles River's RMS segment, the company is witnessing strong growth in the insourcing solutions (IS) business led by the CRADL (Charles River Accelerator and Development Labs) initiative. These days, clients are increasingly adopting CRADL's flexible ...

Core Insights - Charles River Laboratories (CRL) reported total revenue of $1.01 billion for the quarter ending March 2024, reflecting a year-over-year decline of 1.7% [4] - The analysis of international revenue trends is crucial for understanding CRL's financial resilience and growth prospects [1][2] International Revenue Breakdown - Asia Pacific contributed $45.77 million, accounting for 4.5% of total revenue, which was a surprise decline of 17.66% compared to the expected $55.59 million [5] - Other International markets, including Brazil and Israel, generated $16.75 million, representing 1.7% of total revenue, with a significant surprise increase of 199.66% over the consensus estimate of $5.59 million [6] - Canada generated $110.4 million, making up 10.9% of total revenue, surpassing the expected $105.63 million by 4.52% [7] - Europe accounted for 27.3% of total revenue, translating to $276.32 million, exceeding expectations by 5.23% [8] Future Revenue Expectations - For the current fiscal quarter, total revenue is anticipated to be $1.04 billion, a decline of 1.9% year-over-year, with expected contributions from Asia Pacific (5.5%), Other International (0.2%), Canada (10.2%), and Europe (27.7%) [9] - For the full year, total revenue is projected at $4.22 billion, reflecting a 2.1% increase from the previous year, with specific contributions from various regions [10] Market Context - The interconnected global economy influences CRL's financial health and growth trajectory, highlighting the importance of international market penetration [2][3] - The company's reliance on international markets presents both opportunities and risks, making it essential to monitor international revenue trends for forecasting [11]

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Scores as well.What are the Zacks Style Sc ...